Back to results
US 2008/0287432 A1Published application
Compounds and Compositions as Protein Kinase Inhibitors
AssigneesIrm LLC, The Scripps Research Institute
InventorsBarun Okram, Pingda Ren, Nathanael S. Gray
Life of this patent
Estimating the term…
Abstract
The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases.
Claims9
A compound of Formula I:
- in which:
- X1 is selected from CH and N;
- Y is selected from S and NR5;
- wherein R5 is selected from hydrogen and C1-6alkyl;
- Z is selected from C and S(O);
- R1 is selected from hydrogen and C1-6alkyl;
- R2 is selected from C6-12aryl and —NR3R4;
- R3 is selected from hydrogen and C1-6alkyl;
- R4 is —XR5;
- wherein X is selected from a bond, C1-6alkylene and C1-10heterarylene;
- wherein R5 is selected from C6-10aryl and C1-10heteroaryl;
- wherein said aryl or heteroaryl of R5 is optionally substituted with 1 to 3 radicals independently selected from C1-6alkyl, halo-substituted-C1-6alkyl, C3-8heterocycloalkyl, —C(O)NR6R7 and —NR6C(O)R7;
- wherein R6 is selected from hydrogen and C1-6alkyl;
- and R7 is selected from C6-10aryl and C1-10heteroaryl;
- wherein said aryl or heteroaryl of R7 is optionally substituted with 1 to 3 radicals independently selected from —R8 and —OR8;
- wherein R8 is selected from C1-6alkyl, halo-substituted-C1-6alkyl, C6-12aryl, C1-10heteroaryl and C3-8heterocycloalkyl-C0-4-alkyl;
- wherein said aryl, heteroaryl and heterocycloalkyl substituents of R8 are optionally substituted with C1-6alkyl;
- or R3 and R4, together with the atoms to which R3 and R4 are attached, form C3-8heterocycloalkyl optionally substituted with —C(O)NR6R9;
- wherein R6 is selected from hydrogen and C1-6alkyl;
- and R9 is selected from C6-10aryl and C1-10heteroaryl;
- and the pharmaceutically acceptable salts thereof.
18 more elements
Dependencies are inferred from the claim text.